Good morning. Good morning, everyone. Dear investors, analysts, and media friends, very good morning. I'm the General Manager of Capital Market and Investor Relations of Fosun International. I'm Ms. Lu Sun. Welcome to Fosun International 2021 interim results announcement. First of all, please allow me to introduce our senior executives and also classmates on Fosun International. They are the Chairman of Fosun International, Mr. Guo Guangchang. The Executive Director and Co-Chairman of Fosun International, Mr. Wang Qunbin. The Executive Director and Co-CEO of Fosun International, Mr. Chen Qiyu. Executive Director and Co-CEO of Fosun International, Mr. Xu Xiaoliang. Executive Director, Executive President, and the CFO of Fosun International, Mr. Gong Ping. Today, we have morning session to announce the interim results, and also we have our forum in the afternoon session. In the morning session, the senior executives will give us the announcements on the interim results and to communicate with our analysts and investors. Over the past nearly three decades, especially over the past one decade, Fosun International has accomplished its global footprint. We have Happiness and Health and Wealth and also Manufacturing. These are four business lines. We also have C2M, Customer to Maker. Over the past journey, we have achievements. Also we have made a lot of contribution. Most importantly, and it's the time for us to reap the fruit. Going forward, we are going to embrace the exponential and explosive growth. First of all, we would like to invite Executive Director, Executive President, CFO of Fosun International, Mr. Gong Ping, to introduce the financials of Fosun International. The floor is yours, Mr. Gong, Alex. Dear investors, good morning, everyone. On behalf of the Board of Directors of Fosun International, we would like to give you the announcement of our interim results in the first half of this year. You can also take a look at our slides. You can also see some of the key indicators. In the first six months in 2021, we can see total revenue, RMB 70.4 billion. Due to the challenge of the pandemic, you can see our results. You can see that by 11% year-on-year. It is contributed by Fosun Pharma and also Fidelidade and also Peak Re. We can see that we have nearly RMB 600 million, and also for our Intelligent and Manufacturing FFT. Currently, it's called Easun Technology and has also been consolidated, and they have also made a contribution to our performance. Compared with the same period of 2019, you can see 3% increase, excluding Fosun Tourism Group. We all know that because of the pandemic, we have seen the loss of FTG. Excluding FTG, you can see that by 14% from the first half of 2019. You can see that for all our management, we have overcome all the difficulties, we have seen significant rebound of performance. At the same time, in terms of our profit, we have also seen very solid liquidity, we have seen the uplift of NAV. Also for Fosun International as a whole, at the end of June, we have more than RMB 700 billion, basically it is slightly increased by the end of June. You can also see that we can see the earnings per share is around HKD 18.00. In terms of our deposit and also liquidity, you can see that it is RMB 106 billion for our cash and bank balances in the term deposits. We also have the unutilized banking facilities with more than RMB 170 billion. You can also see we have reduced average cost of debt, and that is around 4.4%. The adjusted NAV is HKD 31.65 per share, up by 21% year-on-year. This is thanks to the listed company of Fosun Pharma and Yuyuan and Hainan Mining, and also the improved market cap of Fosun Tourism. In terms of our leverage ratio, you can see it is rather healthy compared with 2020. You can see that in terms of the debt and the maturity, it is also healthy and also safe. As we all know that for Fosun International, we are focused on Health, Happiness, Wealth, and Manufacturing. These are the four business segments. For these four businesses, it's over the past three decades, particularly in the past 10 years, based on the optimization, we entered the new markets and also the niche markets and the new segments. For all these and the four businesses in terms of the mix, and we have to strike the balance. Also you can see that, and excluding the Fosun Tourism, you can see in terms of the net profit, we have also seen very good structure. As you can see that in terms of the operating profit, and we have more than RMB 5.6 billion for the operating profit. You can see up by 40%. It is contributed by the Health. Take the Fosun Pharma, for example, you can see its contribution is much higher. Also due to the centralized and then sourcing, especially for our Fosun Pharma, we have optimized in our structure. We also have Gland Pharma with more than 30% of the business increase. For the Intelligent Manufacturing, thanks to the price hike of commodities, we have made invested in Nanjing Steel and Hainan Mining and then the Tianjin, Jianlong. You can see their profit and contribution is also very robust. You can see for the Intelligent and Manufacturing, you can see that there are more than RMB 1.5 billion increase. Also for the Health, take Fidelidade and Peak Re, and also for the [Yong'an] Insurance, you can see the profit has also been increased dramatically. For the past years, we have also been impacted by the pandemic, particularly for the Fosun Tourism, for Happiness. Due to the loss by Fosun Tourism, there is some negative impact. We're also very confident for the Fosun Tourism in terms of the product and also business model and also our implementation. We had still see very sound growth potential. That's why we are also very confident for the Fosun Tourism. We can also see that for all our four business segments and also for the 10 product lines, particularly in terms of Health. For Health segment, so we have the pharmaceutical devices and diagnostics and healthcare services and products. These three sub-segments. Also for the Happiness, we have the tourism and culture and brand consumption. You can see they contribute to the 80% and less than 20% respectively. For the Wealth, we have insurance and also our Hive and also our asset management and investment. For these three sub-segments in the first half of this year, they contributed to nearly 80%, 12%, and 9% respectively. For our Manufacturing, we have resources in environment and technology and intelligent manufacturing. These are two sub-segments, and particularly over the past nearly 10 years. Thanks to the expansion and also optimization, we have secured our position. Going forward, you can see this is quite optimistic. Let's take a look at our portfolio companies. You can see the top five subsidiaries. For the top five subsidiaries, they contribute a lot. Yuyuan, Fosun Pharma, Fidelidade, Peak Re, and FTG. For these top five, they contributed to nearly an 80% of total revenue, to be exact, 79%, especially for Yuyuan. You can see that in the first half, they have grown dramatically thanks to the fashion and jewelry and also the acquisition of Jinhui Liquor. At the same time, for Fosun Pharma, as I mentioned just now, you can see that the year-on-year growth is more than 20%. For Fidelidade, it is our overseas insurance firm, Fosun Insurance Portugal. You can see year-on-year base increase is more than 7%, for Peak Re the increase is also 22%. You can see that for the Fosun Tourism, we have the negative impact. This year and also next year, we are looking forward to the positive growth. When we review the past three years, particularly over the past seven to eight years, in terms of financials and also in terms of CAGR, you can see that it is well done in terms of our revenue or EBITDA and also our profit or our NAV per share. On the book for the adjusted NAV, you can see the two digits of the growth for our CAGR, because we are advocating the values on the stable growth, particularly over the past 10-15 years. For Fosun International, we put a lot of financial resources into the initiatives to ensure the sustainable new business segments. We have completed the global footprint and from scratch, we have our Insurance and Tourism segments and for Health and in terms of innovative pharmaceuticals and also for the iron and steel and also mining. We have also expanded our business into the Intelligent Manufacturing. We have very sound achievements. I have to say that we have the long-term global footprint, and particularly under the current circumstances, we will continue to go deeper into industrial operation. We are also very confident of the rapid growth in terms of industrial operation. You can see we have already seen a very good scorecard of our industrial operation. For example, take Shede Spirits and Hainan Mining and also Sisram Medical, as well as our newly acquired Wansheng. You can see they have achieved the growth of three digits. I didn't put out two digits. Actually, we have a lot of portfolio companies achieving two digits of growth. You can see that for these, the core growth will be contributed by these industrial players. Also for our Group, we have this balance in both investment exit to reduce the cost of debt in order to optimize our capital structure. We are very happy to see for the rating agencies in February and also yesterday, Moody's and also Standard & Poor's, according to their rating and the outlook of our Fosun International has been upgraded to stable and one notch higher. It is also based on our steady growth. Thirdly, for a lot of businesses, actually, we made investments from zero to one. Also for a lot of businesses, they have been acquired in huge amounts. There were some doubts in the past, but now we have seen less and less doubts. In 2017, we acquired Gland Pharma in India. There were a lot of doubts. A lot of people cast the doubt on our reputation, but you can see the successful IPO of Gland Pharma, and also its share price is also going up. There's no doubt anymore. We also made a lot of investments on our Fosun Health. At the end of last year, and also in the first half of this year, we have also completed the Series A funding. There are also a long queue of investors. We also acquired FFT in Germany, and we have also completed Series A funding, and we are looking forward to Series B funding. Thanks to the support by the external investors and also thanks to the securitization. It also represents that we have already completed the incubation and the development from zero to one. Going forward, we are going to go from 1 to 10 to 100 and higher growth and take our Fashion Group and also by [Lanvin] Group. In the next one to two years, we are also planning the IPO for these listed companies. They are also going forward. It is also well-recognized by the equity investors. For example, in the secondary and also the primary level subsidiaries, we have completed two private placement. One is Sisram, the other one is Hainan Mining. We have completed private placement. With our deeper industrial operation and also the higher profit from our core industries and also better rating, and we are going to see more transparent assets, and we are going to have clearer pricing in order to remove our investors' worries. At the end of our financial reporting, I would like to emphasize that in the past we made a lot of investment on the sustainability. Now we are going to reap the fruit, and we are very happy about the sustainability. We are also confident for the return on investment. Now I would like to switch the gears. I would like to invite Mr. Xu Xiaoliang, our co-CEO, to talk about our business performance. Thank you, Alex. Next, I would like to invite the Executive Director and co-CEO of Fosun International, Mr. Xu Xiaoliang, to give us the introduction to our four business segments. Mr. Xu Xiaoliang. Good morning, everyone. How time flies. We have already seen the ending of the first half of 2021. Next, I would like to give you some elaboration about the Health and Happiness and the Wealth and Intelligent Manufacturing. Let's take a look at some of our highlights of performance in the first half of this year. First of all, let's take a look at our Health business segment in the first half of this year. Based on the global health needs, we have also set up our portfolio covering pharmaceutical, medical devices, and diagnostics and health services and products. Also based on the C2M for our Health segment and for our customer, and we have also set up the one-stop and full-scenario health ecosystem in the medical grade. In the business segment, we have our innovative product matrix. Through R&D and innovation, we try to cater for the diversified needs from our customers. To be more specific, in the first half, you can see that we achieved revenue of RMB 16.9 billion, up by 21%. The growth is primarily driven by three pillars. One is driven by the innovative pharmaceutical products. At the same time, in terms of cosmetic and beauty, which is also growing exponentially. We have also seen it is driven by the medical equipment. Also for the offline medical services, we have also seen very rapid recovery. Also in terms of pharmaceutical segment, in addition to the increase of revenue, we have also seen the optimization of product mix for our HANLIKANG and also HANQUYOU and SUKEXIN and [tablet] and for these innovative drugs. It is a very important driver. Also in terms of the high-margin business segments, particularly our Gland Pharma in India in the first half. You can see the sales revenue grew by 32% for Gland Pharma. For pharmaceutical, in addition to the excellent results, it is also contributed by the continuous R&D investment in the first half. For Fosun Pharma, you can see that we have made investment by RMB 1.7 billion. You can see up by 50% for the R&D. In terms of the innovative drug, you can see 60%. Thanks to the R&D investment, we have also seen that the first in China's mRNA COVID-19 vaccine, COMIRNATY, was launched in Hong Kong and Macau. Also for CAR-T, which is the first cell recipe or the cell therapy in China, actually has got launched as well. Also in terms of our medical cosmetology and also respiratory and also professional medical, these are the three pillars for our business. In terms of medical cosmetology, and for instance, we have Sisram Medical, and it has already gained market share, and now it also moved into, for instance, injection filling and also dentistry. Also we have Da Vinci surgical robots. In terms of installation and also in terms of the number of surgeries performed, actually, we have seen wonderful performance. In terms of healthcare management and also medical service delivery, this is the third pillar for our Health segment. For instance, now we have focused on the highly professional departments and also businesses, and we have organic and also inorganic growth combined together. Currently, now we have 10 hospitals in our portfolio, and we have beds more than 4,000. Also, now we have upgrade Fosun Healthcare into Fosun Health, and we'd like to provide a full scenario and also omni-channel and also one-stop for our customers around the globe, not only in China. This is about Health. Now let's switch gear and look at our Happiness business and segment. Of course, we focus on our family customers, and we have a large offering in our ecosystem for our Happiness segment, not only for our domestic clients, but also for our overseas clients. Here we have two pillars. One is consumer brands and the second is leisure and tourism. In the first half of 2021, we focused on our customer's operation. As you can see here, this is the total revenue. We have a new growth. The total revenue for H1 is RMB 28.7046 billion. Yuyuan has announced its interim performance yesterday, and the total revenue is RMB 22.72 billion. We have a 12.7% year-on-year. We see that for the profit attributable to parent companies, actually has a year-on-year growth of 31%. If we look at its industrial operation income, actually, it has a 58.5% growth year-on-year. The proportion continued to increase to 79.2% and to RMB 18 billion. If we break down and take a closer look, first of all, it's about jewelry and fashion, and it has achieved a revenue of RMB 15.29 billion. It has newly added boutiques of 235 in the first half of 2021. For our Ancient Gold or Guy un series, actually, the GMV in the first half of 2021 is RMB 1.6 billion, and last year, the annual number is RMB 1 billion. As you can see for our Ancient Gold series, it really has an exponential growth this year. We have created a new diamond brand called LUSANT, and it was launched as well. In terms of food beverage, for instance, we have Songhelou Noodle Restaurant, and now it has 32 boutiques, and also we have 27 in our pipeline about to be launched. This year, the total number of Songhelou Noodle Restaurant will be increased to near 100. For our liquor, the Shede and also Jinhui, they have a wonderful performance. For instance, Shede has increased about 133%, also the net profit attributable to the parent increased by 348%. Also for Jinhui, the number is a 56% year-on-year growth in the first half of 2021. Alex has talked about FOLIDAY. Well, FOLIDAY or FTG, it really take a hard blow from the pandemic. It has faced a lot of negative ramification. In in the first half of 2021, the revenue is RMB 2.7 billion, also with a year-on-year decrease of 38.6%. However, now we see a lot of markets and geographies are running out of the pandemic. We forecast a huge rebound or recovery, especially in our domestic market. If we look at the operating cash flow, actually last year it is RMB -726 million. However, this year, it has become a positive number. Also in terms of profit and loss, we can see that in the next year or in the future several years, it will have a very quick rebound. Also for our FTG, in terms of Club Med, they have a wonderful performance. The H1 increased about 171.9%. Also if we look at July's number, actually, Club Med capacity has recovered to 73.2% of the same period in 2019. Also for the business volume of Atlantis Sanya has increased about 152.1% year-on-year. Also we have welcomed more than 2.6 million customers and tourists. Also for Thomas Cook, we have the digitalization journey rolled out for Thomas Cook. If we look at Thomas Cook platform, actually the download times was more than 1.5 million. Now let's switch gear and to look at our fashion business. Under Fosun Fashion, we have several major businesses. For instance, we have Lanvin. Lanvin in H1 2021, compared with 2020, actually, it has achieved 110% of growth in terms of business. Compared with 2019, the number is 40%. Now we have the twin driver or the dual engine. For Lanvin in domestic China, actually, its growth in H1 2021 is more than 300% of growth. It is really furious. Also in our fashion business, although in a lot of markets and geographies, we still have the ramification from the pandemic, but still we press ahead with our M&A. For instance, we acquired Sergio Rossi, and it is a luxury brand for footwear. This is complementary to our current business. Also if we look at Baihe Jiayuan, its revenue achieved RMB 528 million. In 2021, we believe it will break even, and then it will open a new chapter for its next stage of development. Now let's switch gear and look at Wealth. We have a global footprint around the globe, and we have wonderful asset management capabilities, and we have enough dry powder. For instance, we have insurance, and also we have investment fund, and to provide very stable and steady fund in the long run. Also in terms of assets, we have top-notch assets around the globe, and we have, for instance, financial asset and also Hive property asset. Then we match the assets together with the source of funding. It is a nice match-making, and we can marry the wonderful assets with the steady and stable source of funding. The total revenue is RMB 19.65 billion in H1 2021, the profit attributable to the parent company is RMB 2.4 billion. We have 102% year-on-year growth, and insurance is one of our major pillars. For instance, the profit has increased about 172% year-on-year. For Hive, actually, compared with 2020, the AUM is increased by 7.6%. For our Insurance segment, insurance business, it is very important for Fosun International. If we look at the gross insurance premium for the first half of 2021, it is at RMB 27 billion, investable assets is at RMB 170 billion. The combined ratio for our insurance business is on a decline, the return on investment is increasing. For the 2021, for our global asset management, the total revenue is RMB 1.79 billion, the AUM is RMB 150 billion. In the future, our financial assets management will continue its globalization and internationalization journey and to unleash its full potential and also to improve our bottom line and also our top line. We will also focus on the new economy sector and to improve our AUM continuously and also to collaborate with the city fund and to close collaboration with government. We will also focus on, for instance, the non-debt financing, and also investment. Therefore, in the future, we will continuously to have a good match between the assets and also the funding and to form a sustainable growth path. Also in terms of asset management, for our property business, actually, we can see that we have Hive domestic. For the Hive domestic, its AUM is more than RMB 400 billion. In the first half of this year, we have a newly investment of RMB 9.1 billion. In Xuhui Binjiang, we have wonderful projects as well. If we look at Hive overseas, we focus on Asia- Pacific and North America and also EU. The AUM is more than RMB 13.2 billion. The year-on-year growth is around 10% compared with 2020. We have made investment in the first half of this year at RMB 0.62 billion. Now we have the dual headquarters. We have one headquarter in Shanghai and another in Singapore. We believe it is a very important way to go forward to provide us with a stable and a steady lifeblood. It is vital for us to go on to a sustainable development. Now let's look at the last business we have, that is the Intelligent Manufacturing. We take a closer look at the upstrea- and also midstrea-, and also downstream- layout. In terms of the upstream, and we lower the cost and improve efficiency, and we focus on, for instance, raw material. We have made new acquirement and for instance, the Wansheng, which is a leading company producing phosphorus flame retardant. Also in the midstream, again, we have internal incubation together with inorganic growth M&A and to better serve the downstream platforms. The total revenue is RMB 3.57 billion, and we can see we have a huge year-over-year growth of 202.2%. Also we have the profit attributable to owners of the parent is RMB 1.63 billion, and it is mainly due to the growth from NISCO and also Hainan Mining. NISCO really has a wonderful performance in the first half. For instance, the revenue year-on-year increase is 58.4%, and the profit year-on-year 102.7%. For Hainan Mining, well, now we are in the up-moving cycle and also we implement lean management. As you can see here, the revenue is increased by 61.02%, and also profit is increased by more than 2,000%, nearly 3,000%. For NISCO, for Hainan Mining, we are also focused to align our goal with our national goal in terms of carbon peak, and also carbon neutrality. In terms of profit and also revenue, as I have talked about, NISCO has a wonderful growth in the first half of 2021. In the future, it will also move into the new material industry, and it has acquired Wansheng Company. Wansheng, as I have said, it is a leading platform for phosphorus flame retardant. On the other hand, we are making new investment in terms of plants and also factories and facilities to enhance our output capacity. Hainan Mining, it focus on the oil and gas businesses and also ground mining to collaborate with the Hainan government and to provide a complementary role in our total business. In terms of profit, it has a huge improvement and it has the existing platform as ore mining. For the Roc Oil, it has made a successful acquirement for a patch of tight gas. It has finished private placement, and we see over subscriptions from the market, from our investors. This shows that the market is having a very booming phase in the performance. We have Besino and also FFT, and also JEVE Power and also Wansheng. If you look at their top line and also bottom line, both are increasing and also their capacity is expanding. They are putting in place a consolidated supply chain and industrial chain. For all these enterprises, they are talking with the investors, and they have thought highly by the primary market. They have introduced the strategic investors ongoing forward. This is about Fosun's performance in terms of H ealth, Wealth, Happiness, and also Intelligent Manufacturing highlights regarding to our business and the performance. Now I'd like to hand over the microphone to Mr. Chen Qiyu, and he will talk about, for instance, our organizational involvement and also our strategy optimization. Without further ado, well, I'd like to hand over the microphone to Mr. Chen. Hi. Thank you, Mr. Xu Xiaoliang. Now I'd like to invite Mr. Chen Qiyu, the Executive Director and also Co-CEO of Fosun International, to talk about corporate governance. Hi. Now it's my turn. Well, I will talk about corporate governance, but not only about corporate governance, but more about our development plan. How can we develop it better and also faster ongoing forward? Basically here, I'd like to talk about the three aspect, that is multiple growth, entrepreneurship, and also greater responsibility. In terms of multiple growth, we'd like to center around our investors and to make ourselves a great company. To become a great company, not only in the eyes of our customers, but also for the market and also for the investors. In terms of entrepreneurship. We'd like to become the best employer and also for the greater responsibility, great accountability. That is, we want to interweave ourselves into the intricate network of that of the society, and to contribute more to the society as a whole. In terms of multiple growth, well, next year will be the 30 years anniversary for Fosun International, and we can divide our journey into four phases. From 1992 to 2000, basically, we put down our roots in China and also the overseas market. In 2001 to 2007, we focused on the Chinese market, but also we rapidly expand to the overseas market. By then, we already have our real estate business and also Health business, and also our gas and mining business. In 2008 to 2018, here, we put together Chinese momentum with our global resources, and we have the twin driver for our future growth. We have the framework for our investment and philosophy. Since 2019, here, we focus on industrial operation. We need to deepen our industrial operation. In the past one and a half years since the pandemic, actually, we focus on industrial operation. This is the top priority for our current business. Also our investment is to serve the industrial operation to play a complementary role. Then we have make our intelligent manufacturing into a standalone segment. Well, in terms of strategy, we always think about how we can create an ecosystem that can serve more than 1 billion family customers. We focus on, of course, industry operation and with industrial investment. Well, this is something that remain unchanged ongoing to the future. Also, we have the FES system. The second is to create a FC2M ecosystem, as you can see on the right. Now we're in the middle of the internet era. When we look into the future, well, before Fosun only focus on M&A. Ongoing to the future, we will also put a C-end on top, and then to form the FC2M ecosystem. Also the third is about innovation-driven, and to have not only product innovation, but also management innovation. Fourthly, we would like to build our second version of globalization in the future process of globalization. This is also very rare for Chinese enterprises to be globalized. Talking about the FES, our Fosun system. We continue to focus on the technology and innovation and also investment and industrial operation. Talking about FES, E refers to entrepreneurship as well as our ecosystem. Under FES, we have five basic models. One is growth. Strategically speaking, we have to plan and also advocate the sustainable growth of all our business segments. Secondly, we need to have our organization or our mechanism to ensure the growth. Thirdly, we need to have a very effective ecosystem based on all the global families. We can come up with our ecological synergies to serve our global families and the customers. Of course, we attach the great importance to risk control. Also the lean operation. From top to bottom, we are going to guide the evolution of all our business. Also, first of all, talking about the twin drivers of industrial operation and investment. The first thing is about industrial operation. Over the, particularly the past 20 years, we already have the closed loop of operational management, and we have our strategic planning and also our budgeting and talent planning, and then also the evaluation and also the rewards and punishment and also the operational supervision. We have both a short-term and a long-term mechanism. We also have the 1 + 2 + 7, and we have a long-term of 10 years planning. Also we focus on the short-term synergies and also improvement. In terms of our industrial investment, this is also a very important driver. Talking about industrial operation and investment, they cannot be separated from each other. We are using the global competency to empower our growth and operation. In the past for Fosun Pharma, we always said that one is an internal growth and also external growth, and also the integrated growth. That is also the essence of the twin drivers of industrial operation and investment for all our business segments. You can see that in 2017, we acquired Gland Pharma. For our global footprint and also in the global generic drugs, we have also boosted our global presence. Also for Gland Pharma, it is the top five pharmaceutical company in the India market. In the Happiness, as mentioned by Xu Xiaoliang, we have acquired the spirits and also the liquor. You can see that these are the implementation of our strategic planning. For Fidelidade, we have acquired the company in Peru. They moved from a European-based insurance firm to expand into the South American market. For FFT and also JEVE Power, we are also engaged in the automotive landscape. For the FC2M. First of all, we always put the C-end on the top because for our Fosun's growth in the past, we put a lot of emphasis on the M. That is more about the M&A and then for our product services. For the C-end, it was also very strong in the past, but due to the impact by the internet, and if we want to continue to center on the internet and online marketing, and that is still less capable. That's why we also try to push forward the FC2M, particularly C-end on the top. Over the past couple of years in terms of the integrated marketing and digital marketing, and also the product co-creation, we already have more than 376 million registered users and 200,000 total number of high-power users. Also, the satisfaction rate is 75%. It is still on the rise. Of course, we have to create good products and by different means. For example, BD, R&D, and investment, and then also business and driven incubation, et c. We try to create more good products. Maybe you can already feel that in Fosun ecosystem. That is more about our good products and also biosimilar for Henlius and also the CAR T from Kite and Henlius and Harbor, Club Med, et c. You can tangibly feel these products and services. In terms of globalization, over the past many years since 2007 and 2008, we always adhere to this core competitiveness. We started from both industrial operation and investment. Fosun has already developed a very truly global landscape covering all these continents. In the process of globalization, there are two trajectories. One is for the China's market development. We acquired global resources and brands and introduced them into the Chinese market, including Club Med and etc. At the same time, we also have our Chinese businesses going global. For example, for our artemisinin and our pharmaceutical, and also our pharmaceutical and registration marketing in Europe and America, and also for innovative drug and license out, et c. Of course, we also introduce the innovative drugs into China's market such as license in. Both license in and out. In different business segments for our fashion and also our sports businesses. We have both introduced global brands into China's market and also go global. When we introduce these brands into China, we put a lot of emphasis on our direct contribution. We have the dual headquarters, and this is also part of the innovative mechanism. In order to grow rapidly and also about our multiple growth, and we are going to emphasize on the marketing and products and also globalization and also the ecosystem multiplying. Here you can see by means of the multiplier effects, we are going to add more values, we are going to contribute more cooperative values. For our organization, we have to ensure the efficiency in order to ensure the multiplier growth. For example, partnership mechanism, incentive mechanism, and also the key talents training. For our partnership. Since 2015 and 2016, when we firstly launched the global partnership on the top. You can see it is deepened, we have more than 100 global partners, 108 to be exact. Going deeper, we have innovation, and also industry segment, and investment, and also function line partners. For our portfolio companies. We also have the partners for the operation and business units. We are also trying to optimize this mechanism. We also have specific requirements. For example, we have the culture value assessment. This is very important for our partners. The performance and innovation-driven assessment, et c. There are also very clear criteria. Also for the co-creation. Also it is very important about the sharing of the benefits and the incentive for the past years of evolution. We have short term, midterm, and the long term, and also by cash and by equity, and also multilevel incentives. We put more emphasis on the short term and the terms and incentive should be launched in short term. In order to retain our talents, we should share more our profit and benefits. On the top we have the partnership incentive. Also the key talent is also very important pillar. It is also about how strong we are going to be in the future. For all these key talents from our new graduates from the universities and these excellent graduates. Step- by- step, we have set up the development mechanism for key talents. For all these key and excellent talents from the new graduate, and we have also acquired these entrepreneurs, and we hope that we can then share our development and growth targets with them. Ultimately, it is hoped that they can become our partners in different levels. Then it is about a greater responsibility. We hope that we can achieve the common prosperity. Self-improvement, teamwork, and performance and contribution to society, that is in our initial value initiated by Mr. Guo for Fosun. Even now, these values are very important for our sustainability. Particularly, over the past three decades, we already set up a very solid foundation. For us, we are more than willing to make more contribution to the society. In terms of responsibility, as a corporation, we always talk about sustainability. Let's take a look at the MSCI rating. It is also our focal point over the past years. You can also see the MSCI, and we have A rating, HSI A +, and the rating by different international organizations. We are involved in all these ratings. Our purpose is when we involved in this rating, and we can also push forward the upgrading of our corporation. In different indicators, you can see very good ratings. When we talk about the carbon neutrality, and also the carbon peak or carbon neutrality. Last year, and also this year, Fosun in multiple times, we organized the workshops to talk about how to help reach the carbon peak and neutrality. For Hainan Mining and Nanjing Steel, they have their models. For Fidelidade and also for our Fosun Pharma, they have different models. Ultimately speaking, we try to make progresses for carbon neutrality. We have also set up our strategic planning for the carbon peak by 2030 and the carbon neutrality by 2060. In terms of other initiatives for responsibilities, you can see we are always involved in these initiatives. Since the beginning of pandemic, we are one of the first, probably the first one, and we support the global fight against the pandemic. In the most difficult time at the outbreak of pandemic, and we have 5 million medical suppliers to be purchased into China. These 3 million medical supplies are urgent and needed. In the global fight against the pandemic, Fosun has also set up a benchmark for the support for the global fight. In the first place, Fosun is one of the first batch of companies to protect Hainan in the flooding. For the Zero Malaria in Africa and also for the rural doctors. We are also engaged in all these social activities. For corporate governance, we promote sustainability for responsible operation, responsible investment, and responsible procurement. We have set up a ESG commitment in the level of our Board level. That is my presentation. Thank you for your listening. Thank you, Mr. Qiyu. Next. Now is the time for management Q&A. We would like to open the floor to questions, both online and offline. Please. We would like to invite our first guest in the first row. The second one in the first row. Good morning. I'm Angie from Hong Kong. We have focused on Fosun International for a long time. My question is for Mr. Guo. For Fosun, over the past nearly 30 years, and particularly over the past 10 years, and in terms of our strategy and also for your evolution and also for your growth, what's your observation? What's your forecast? Also currently and also going forward, what is your expectation for Fosun International? Maybe you can give us some of your idea. Actually, Mr. Chen Qiyu has already give us the summary. Because in his slide, there's a form. Next year is also a very important year because the next year marks the 30th anniversary of the founding of Fosun. Now we are going to have our own memory. We will continue to look ahead. We cannot just review the history. We are not an old guy. We are still a young guy. We are still a startup and to look ahead. Recently, as mentioned, we talk about the 30th anniversary, of course, we want to review what happened, particularly in the past 10 years. We have both experience and lessons and also achievements and results. The one of the highlights is that we have our footprint now. We are playing the chess, now the presence, the layout is already done. That is our global footprint is already made. There is also a process of anti-globalization. How about our globalization? Now we have a very strong force of anti-globalization. Now we are taking deep root in China. If we go global, it is more valuable going forward. If you can really take a deep root in China and you can also integrate global resources, there are not many other companies like this. I think it is a good timing. We want to mobilize our global-A force of globalization to make more contribution to our customers and to the nation. We want to bring into play our globalization to create more values for our shareholders. Next, we have the layout of our industrial operation that we have in Health and Wealth and also Happiness, and also Manufacturing. We also completed a lot of businesses from zero to one. Take Yuyuan, for example. Like one bowl of noodle and two Steamed Buns and Pramerica, and also our health insurance and also Peak Reinsurance. For all these businesses in the past, we made a lot of investments without output. We did a lot of process from zero to one. Starting from now on, we have started to reap the fruit and create more values for our shareholders. Next, in the whole process of development, in addition to the investment on the spirits and liquor, we have also made investments on the turnaround in order to make a lot of endeavors for turnaround. Over the past years, maybe they have not been reflected on the profit in our statement. We made a lot of investment take by [Yuyuan] and Babytree, et c. However, for all these investments in our ecosystem, we have to make these investments, especially if you want to complete on FC2M. They are very important, very good sectors. That's why we have made a lot of investments and also initiatives. Over the past years, we completed the global footprint and industrial operation footprint, and then we have also explored our FC2M. We have done a lot of business from zero to one, but now it is the time for faster track and faster growth. That's why you can see very rapid growth this time. It doesn't mean that we have done an excellent job, but I think that after the years of our growth, and of course, everyone is making utmost endeavors and efforts. I think that is also result of our accumulated efforts, and we have already seen the time for fruits. In the future, we will continue to bring into play our global capabilities and also unleash our capabilities for full- business segments, and then also develop our capabilities of FC2M and make more values for our customers. We believe that we are going to enter into a stable and also rapid phase. We will continue to stick to industrial operation and investment. These twin drivers will continue to develop our FES system. Mr. Chen Qiyu has already given us a very good introduction. We will continue to develop our global partnership system for corporate growth. Mr. Chen Qiyu also said that the thickness, the robustness of your talents will determine your width and also the height of your cooperation. That is about how strong your talent is. Of course, we have a very strong talent now, but it is still far from enough. We will continue to work harder. Thank you. Thank you, Mr. Guo, for your answer. For our second question. For the gentleman with the glasses. Thank you. Please use the microphone. What is your take on the future development of your white wine or the white wine market? What is the forecast for the white wine market and also the strategy on going forward? Not only the white wine, do you have any future underlying targets to be included in your portfolio, not only for the white wine? Actually in August, we see that the government has a panel discussion with the representatives from the major white wine companies in China, and basically it is to better regulate the white wine market in China and to step away from the indiscreet investment. Otherwise, there will be unbridled competitions, this will lead to bubbles in this market. As we can see that in the future, we will continue to have very close communications with the government in terms of the policy to align towards the same goal and to put everyone on the same page. For Fosun Group, we are quite upbeat about the market, especially the white wine. Basically, we believe it is a very important part of our family reunion and also family gathering. Now Fosun has made investment in Shede and also Jinhui Liquor. We have a very clear-cut strategy and tactics on going forward. Basically for Shede, of course, we need to be patient. To have the good wine, we need to wait. Therefore, for Shede, basically, they will have more or less the same strategy on going forward and to focus on the products and to focus on the quality of the product. For Jinhui, first of all, they are based in Gansu, which is in the western part of China. For their strategy, of course, we will encourage them to go beyond the original market, to go beyond Western China and to move into other markets and geographies as well. Of course, during the way we will follow up, we'll keep a tab on the changing policies and also strategies from the government. During the way on going forward, we will, for instance, to allocate personnels onto Shede and Jinhui and to encourage an orderly competition in the market. Now the lady in the first row. Hi. I come from [Meiri] Economic News, and I have a question. For Fosun Group, could you update us with the information regards to Comirnaty and our vaccine? Well, maybe Mr. Guo can provide some information here. Why I'm the most suitable person to answer this question? First of all, in the first half of 2021, we have a wonderful performance out of our Health segment. It is due to our layout and also business arrangements beforehand. On the way, it is not a smooth ride. However, we charge ahead and we make the investment, we do the cooperation, and this lay a solid foundation going forward. Now in China, especially, in our domestic market, actually, we really rein in the pandemic. Also for our food and beverage and also for our tourism industry in domestic China, we have a very strong development. First of all, we need to think highly of the rein in condition on the pandemic. This provide us with a solid foundation to develop our business. Secondly, not only we contain the pandemic, but also we are the trailblazer. For the Chinese market, we are also the trailblazer in terms of vaccine and also vaccination, and we have several pipelines in sync. Well, now for Fosun Group, we have Comirnaty. This is the result of the cooperation between us and also BioNTech from Germany. Apart from vaccine, actually, Fosun International, we always focus on the drug R&D for pandemic. For instance, we have the multiple antibodies, and also we have the small molecule drugs. Also, we have the license-in drug, also in license-out drug for African market and also for Indian market. Regarding to Comirnaty's clinical trial and also approval, well, actually, we are collaborating with, for instance, the NMPA and also CDE, and also the central government and the Shanghai Municipal Government. Well, the only thing I can say is that we are pressing ahead the vaccine approval and vaccination according to our schedule. BioNTech yesterday announced that for this vaccine in the U.S., it has gained official approval from the United States government. This is the first one in its kind, and I think this is a milestone for our vaccine. Of course, we are looking forward to gain approval from the NMPA as soon as possible and to launch it into the mainland China. We firmly believe in its efficacy and performance in fighting against the pandemic. Many thanks to our teams and also kudos to BioNTech. In May 19th, 2021, and Fosun has already signed the exclusive agreement with BioNTech. We will invest in a joint venture company in Shanghai to have a local production and local commercialization going forward. We are pressing ahead with this agenda in a timely manner and according to our schedule. Thank you. Well, thank you, Mr. Guo. The gentleman in the red t-shirt. Hi, my question goes to Mr. Guo. Actually, I see a very clear-cut financial strategy that is to lower the financing cost and to improve the credit rating, and also to maintain a balance between investment and the divestment. What is the financial rationale behind all this? Also, for instance, could you elaborate on, for instance, the future goals? What is the balance of investment and divestment, and also what is the different proportion of different financing tools? Well, actually in our report, we have a talk about our financial goals. That is, first of all, is to improve our credit rating and also to use our financial management to drive the core competency improvement of our core businesses. We have the so-called 361 Strategy, that is in the current existing businesses. Well, especially for our large companies to achieve 30% of year-on-year growth, and also for the companies that in the high growth period, they need to achieve 60% of growth. We have a different target for our enterprises still in the incubation period. This is a very clear-cut strategy and also goal. Actually, if we look back five years, our core businesses, our subsidiaries, their top line growth, and also bottom line growth has been very strong. If we look at our dividend payout ratio in the past several years, they are all very stable. Also for our dividend payout last year is more than RMB 4 billion, and this year it will be more than RMB 4 billion annually in terms of a dividend payout. We will continuously to promote the stable cap structure. Currently, our leverage ratio is around 50%. We believe it is healthy and also comfortable. We will continue to lower our financing cost and also to venture into innovative financing. For the 50% of the leverage ratio, we believe it is very healthy right now. Actually for Mr. Gong and also Mr. Qiyu, they have already talked about in the past three decades, development, especially in the last 10 years, we moved into a lot of new products, new segments, new business, and also new geography. We have done a lot of R&D. Actually, the investment is from the Group level, the headquarter level. However, now in the future, actually, the major investment will be made by our core businesses and also subsidiaries, but not from the headquarter level. Also for our main businesses, actually, they have already traveled. They have completed the zero to one phase. They are now in the one to N phase, and they have their own capability to do new layouts, to do new asset allocation and also investment. That is why we say that we are now in a period to reap the fruits. In the past several years, we have the twin driver, that is investment plus industrial operation. Now, for instance, Yuyuan has made proactive investment in Shede and Jinhui Liquor, and also Nanjing NISCO has acquired Wansheng. For Hainan Mining, well, they have acquired, for instance, the tight gas and to further enhance their internal capability and also Fidelidade. They have made acquiring into a company in Peru. All these investments have been done by our subsidiaries and core businesses. At a Group level, actually, we maintained a balance between the investment and the divestment. Also that is why that Moody's has upgraded twice our credit rating. For the improved credit rating and also the investment made by our core businesses, well, this enable us to lay a very solid foundation on going forward. Also our NAV per share is more than HKD 30. Actually, the market cap is RMB 160 billion, including the shareholding from Fosun Pharma. Also we have a huge number of non-listing assets as well. Also if you look at our cash reserve, our liquidity is really good right now. Also with the effort from our CEO, we have a very good relationship with more than 100 banks, and we have a large amount of unused bank line of credits. Also since last year, 2020, we began to focus on the equity financing as well. Due to the fact that we have the exponential growth in business, we already demonstrate our capability, and we are held highly by the investors for Fosun Health and also for Henlius and FFT, and also for Fidelidade's IPO. Also this year we will have Free and also Hainan Mining's private placement. Also we have other projects that will be supported by equity financing. You can see the market faith and also confidence for our business. This is all I can say for this question. Thank you for your question. Thank you, Mr. Guo. For the next question, well, I'd like to invite the lady in the back row. Hi, I'm from First Finance. In the interim report, you talk about FES. What is FES and how to implement it into your business? Also, what can this FES bring to our investors? Well, thank you. Thank you for your question about FES. Well, first of all, when we talk about FES, we need to go back to the past 30 years. In the past 30 years, well, we have the twin driver, industrial operation plus industrial investment. During the past 30 years, we have a lot of best practice. We'd like to galvanize these best practice and to cascade down, to record them, and also cascade down to every level of our company, and to provide a guidance for our daily operation, and to support mutual enabling across different segments. Not only we have internal best practice, but also we are in a learning curve. We learn from the top-notch companies around the globe. We learn from our competitors. To combine with our internal best practice, and that is about FES system. Ongoing to the future for the FES system will continue to be supported by industry operation and industrial investment. Here, actually, it is a high-level summary of our global mission and vision, just like Mr. Guo has talked about right now. Also how to implement FES or how to cascade down this FES system. Well, FES focus on organizational structure and also talents. We believe this is our most precious asset, because without talents, we cannot travel better and also further. Talents and also our organization is the best asset that we need to have, and also to encourage, for instance, the co-creation spirit, co-entrepreneurship spirit among our talents. This is the first level. The second level, well, is about the growth. Not only we need to have the absolute growth in numbers, but also in value creation. We hope that for Fosun International, Fosun Group, when we talk about value growth, we can also have quantitative measures, or just like Mr. Gong has talked about. Also the third level or the third aspect for FES is about ecosystem. We are a huge conglomerate, and we have a jungle-like ecosystem. How to mutually enable each other. The fourth is about lean management. Fifth aspect or the fifth level is about risk control and also compliance. For instance, to have a better risk control over legal affairs, and also to take a closer look at the monitoring risk and also policy risk, and also maintain financial discipline. This is about the five aspects or the five levels of FES. During the implementation of FES. Well, FES is not only a theory. The important thing is how to put theory into practice. We encourage everyone to participate, to pitch in the implementation of FES. At headquarter level, we will have the FES implementation task force. The ultimate goal is to create added value and to improve the satisfaction level of our investors, our partners, and also our employees. Thank you very much. Well, thank you, Mr. Wang. The next question, the lady in the yellow shirt. Hi. Dear classmates from Fosun Group. Well, now a lot of global investors, they focus on ESG issues, environment, society, and also governance, corporate governance. For a lot of markets and also geographies, well, we receive the negative ramification from pandemic, and ESG seems much more important than ever. For a lot of investors, they focus on corporate governance in the post-pandemic era, and we believe that to have a better corporate governance, we will have a better resilience. My question is, for Fosun Group, in terms of ESG, what is your goal for the ESG rating? Well, in terms of ESG rating target for Fosun Group, of course, we want to be among the best. On one hand, well, Fosun, we are a Chinese company, but also we have a global presence in different markets and geographies. ESG is a focal point for global investors. As a global corporate citizen, we need to hold up ourselves against the benchmark or the criteria of ESG. For a lot of investors, well, ESG is also a very important part in their final decision. We always talk about the growth in our profit and also revenue, but not only they focus on the profit and the revenue growth, but also they will try to see what is your corporate governance and also what is your social contribution. In terms of the waste management and also for your employees, whether they live a good and a relatively bad life. Is it possible that you have very low wages for employees? That's why you have a very high revenue. How about your input into your employees? For all your employees, and for the next three to five and 10 years, how about the employee growth? How about the contribution to the communities and in terms of the charity, et c? That's why we need to make some input and also planning, and also execute these plans. This is a very high requirement and also a very high criteria. For example, we have 100 portfolio companies, maybe you have high requirements on our 80 portfolio companies, and less strict requirement on 20 companies, then it doesn't work. That's why if some of your business do not do well in ESG, then the investors will not value your whole group. That's why we want to have a consistent criteria on ESG covering the entire business. We hope that wherever we are in the world, we have very consistent and high and strict requirement on ESG environment and social responsibility and also the corporate governance. If you can do well in these three pillars, coupled with very good financial results. If you have at least two good results on ESG and financials, then you can become a sustainable company. I think that is our observation on ESG. Thank you. Due to time limit, the last question. The second row on the left, that gentleman. Yeah, that's your turn to ask the question. The last one. Yeah, I have actually three questions in total. First, I would like to thank our senior executives to give us the introduction to the results. The first question is still about the vaccine. I do not want to ask the timing. There's still a lot of question about when it can be launched. My question is out for Mr. Guo, you are referred to as the Chinese Buffett, you put a lot of emphasis on investment. For our fund, we have also acquired many shares in Fosun. For me, yeah, the safety and certainties are very important. My question for Mr. Guo on vaccine is that I do not want to ask the timing. How about the probability to get approved? Because for me, I want to bet the probability. For you, what is the probability to get your vaccine approved? Yeah, maybe you can ask all these three questions together. It is not a question, it is a questioning. The second question, and another hot topic is about common prosperity, like pdd.com and Tencent started to answer this question. Fosun is also a very important private enterprises in China. What's your observation on this topic of common prosperity? The third question for Fosun Pharma in Asia, and the market has already been lower than the share price, and also the debt rate is also very low, and you also have very good results. Of course, we hope that maybe we can also have a higher confidence. Maybe you can convey a very clear message. Even without the vaccine, you are very optimistic about the future prospect of Fosun Pharma, especially in terms of the share price. Maybe I have another request, a personal request. As I know that for Mr. Guo, I know that you have very busy schedule, and you will also practice golf and as a minority shareholder. Maybe if you have free time, I hope that I can invite you to play golf with you. This is my request. Thank you for the three questions and one request. We only have four minutes left, so I would like to give the floor to Mr. Guo to answer this question. Maybe one- by-one. In terms of the private placement on the Fosun Pharma. Actually, now you can see that we go deeper to all these portfolio companies for the Group to increase the investment. Because actually, you can see that we have already increased a lot of the share. For example, around RMB 1 billion, and we increased the shareholding of Fosun Pharma by RMB 1 billion. Actually, you know that in terms of the time window for our Fosun International, we have very limited window. Our Fosun International is more than willing to increase the shareholding. It should be in compliance with the laws and regulations. We are very optimistic about the value of Fosun Pharma, we are willing to increase the shareholding. Let me answer the question for the topic on common prosperity. When we talk about common prosperity, this is also our goal for Fosun, our core value. At the very beginning of startup, on self-improvement and teamwork and performance and contribution to society, we are more than willing to create the values for the society, and we hope that we can do more for our society. This is our original aspiration. For common prosperity or commonwealth, I think there are two dimensions in our consideration. We hope that we can grow our corporate business to promote the common prosperity. Particularly, recently, as mentioned by our Chinese leaders, we hope we can promote the common prosperity by means of high-quality growth. For example, we can grow our business to enable our employees to have a better and also more reasonable and, of course, a legal income. That is one dimension. The second dimension that in addition to our employees, we hope that our customers can also be more prosperous. We also have very important business to make our customers healthy. That's why we put emphasis on the four business segments and Health and Happiness or Wealth and Intelligent Manufacturing wealth. It is also to enable our customers to be wealthy. We have insurance and wealth management businesses. Also, in terms of products, we also hope that we can let our customers to enjoy our products and to have the spiritual wealth on top of the physical wealth. In addition to the employees and customers, we also hope that we can grow our business to create the prosperity for our investors and shareholders. We can help you to increase the wealth. That is also part of common prosperity for all our partners in our ecosystem, for all our stakeholders. We hope that we can grow together and that we can create and innovate together to achieve common prosperity. You can see that through the high-quality corporate and growth to make our employees and customers and shareholders and also all our partners to become prosperous together. Also, we are using our Fosun Foundation to actively get involved in the social and charity campaigns and initiatives. For example, we have a Rural Doctors Program now. You can see through this Rural Doctors Program, we want to promote the development of these rural areas by cultural and also the young people and startups and also through different charities and CSR initiatives, especially for their Poverty Alleviation and the Rural Doctors Programs. We have also been awarded as the Excellent Company for the Poverty Alleviation by the government. We will continue to strengthen our efforts to promote the programs and all these CSR, including the Rural Doctors Programs et c, to achieve common prosperity. This is part of our ideas on this question. Of course, we will continue to make evolution. Well, first of all, I would like to thank you for being the investor for Fosun Pharma. For Fosun Pharma, you cannot just take a look at our vaccine. We have a lot of good products. We have Henlius, that is good, Gland Pharma, that is good. Also, we have CAR T. We have many good products. Also Da Vinci robots. You can already see that in China, we want to set up a joint venture for Da Vinci robot. It is already public announced. The second response. Last March, we cooperated with BioNTech for the vaccine development. What's your question again? One is certainty, the other is safety for investment. You know that is the least safe and the least certain investment at that time. At that time, maybe the shareholder is not the top priority for this vaccine cooperation with BioNTech. Our top priority is to have one more option for the country. We hope that we can have all the optional technologies to help the fight against the pandemic. At that time, we didn't think about to use the vaccine to increase the value for Fosun Pharma. For Fosun Pharma, it does mean that vaccine is all of the equation, and the vaccine is only part of our portfolio as part of the equation. The vaccine development is only one of our directions for Fosun Pharma. It is not the huge contributor. Our original aspiration for vaccine is that we can go back to normal and to have one more option to everyone, to the nation. That is what we want to do. No matter what the result is, we are going to do this. Next. Currently, the whole process is going forward very normally. We are a country of rule of law. Everything is very transparent and also just and equitable. In the national level and in terms of the prevention for the COVID-19 and also for all the government and authorities, they have given us sufficient guidelines and support. I have not seen any intentional delay of the approval. Just we follow the legitimate process and formalities, we are facilitating the approval. We have already been supported by the local and national supports. There's no doubt about that for the whole nation, for all of us, and also for our national future, we are always very optimistic. Talking about the common prosperity, it was already said by Mr. Deng Xiaoping. First of all, some people can be wealthy first, and then we have to reach in common prosperity. This is a part of the national strategy, and common prosperity is also our original aspiration from the start. We talked about this at the very beginning, self-improvement, team spirit and performance, and contribution to the society. Our ultimate goal is to make contribution to the society. Talking about the contribution to society is not just to distribute the money or to do charity by the bank loans. First of all, we have to create the values for our customers and for our partners, for the country and the society. We have to do the right thing, and we have to do something right for the whole environment at the same time. We have to do more CSR campaigns. That's why I'm very supportive of Rural Doctors Program. For common prosperity, there are two scenarios. Sometimes maybe we have less capability or less intention. Maybe we can use the education to empower them to let them to become prosperous. It doesn't mean that we have to teach them how to become rich, not just to give money to them. The second is not about the capability or the intention. Maybe it is because we have no probability. Maybe they have the intention, but they don't have the capabilities. For example, we are using Rural Doctor Programs then to help them, maybe because of the disease. For a lot of kids and older people who are living in the villages, and if they are sick, then maybe these young people have to go back to the villages, then they cannot become prosperous. For those people who are not capable of becoming rich, we can help them. For Fosun, we want to do a lot of CSR and charity initiatives. We also hope that we can effectively help people with common prosperity. For all the value created, it is not an easy job. For each penny, it's not an easy job. We cannot waste money, and we have to maximize the value. Thank you. I would like to thank all our management and also thank you for your participation. Fosun International 2021 interim results announcement morning session ends now. The afternoon session will begin at 1:30 P.M. We're also going to introduce four business segments about Fosun International with batch, and you can come back